CervoMed reports Q2 EPS (27c), consensus (45c)
PremiumThe FlyCervoMed reports Q2 EPS (27c), consensus (45c)
1M ago
CervoMed Inc trading resumes
Premium
The Fly
CervoMed Inc trading resumes
2M ago
CervoMed Inc trading halted, volatility trading pause
Premium
The Fly
CervoMed Inc trading halted, volatility trading pause
2M ago
CervoMed initiated with an Overweight at Morgan Stanley
PremiumThe FlyCervoMed initiated with an Overweight at Morgan Stanley
2M ago
CervoMed Discusses Neflamapimod in Virtual Investor Event
Premium
Company Announcements
CervoMed Discusses Neflamapimod in Virtual Investor Event
2M ago
CervoMed to Participate in the Emerging Growth Conference
Premium
Press Releases
CervoMed to Participate in the Emerging Growth Conference
2M ago
CervoMed announces addition to Russell 2000, Russell 3000 Indexes
PremiumThe FlyCervoMed announces addition to Russell 2000, Russell 3000 Indexes
3M ago
CervoMed announces completion of enrollment in Phase 2b RewinD-LB trial
Premium
The Fly
CervoMed announces completion of enrollment in Phase 2b RewinD-LB trial
3M ago
CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies
Premium
Press Releases
CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100